Stanislas Quesada
Overview
Explore the profile of Stanislas Quesada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Quesada S, Penault-Llorca F, Matias-Guiu X, Banerjee S, Barberis M, Coleman R, et al.
Eur J Cancer
. 2024 Dec;
215:115169.
PMID: 39693891
Background: Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency...
3.
Joly F, Bazan F, Garbay Decoopman D, Garbay D, Ouldbey Y, Follana P, et al.
JNCI Cancer Spectr
. 2024 Dec;
9(1).
PMID: 39673810
Background: Maintenance niraparib at an individualized starting dose (ISD) is established in platinum-sensitive recurrent ovarian cancer (PSROC). However, patients' perspectives on the burden of prolonged maintenance therapy have not been...
4.
Chatelet C, Quesada S
Bull Cancer
. 2024 Oct;
111(12):1084-1085.
PMID: 39455328
No abstract available.
5.
MBaloula J, Tougeron D, Boileve A, Jeanbert E, Guimbaud R, Abdelghani M, et al.
Eur J Cancer
. 2024 Oct;
212:115051.
PMID: 39366210
Background: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. The POLO trial showed that olaparib (PARP inhibitor) improved progression-free survival (PFS) but not overall survival (OS), when used as maintenance...
6.
Colombo P, Taoum C, Fabbro M, Quesada S, Rouanet P, Ray-Coquard I
Crit Rev Oncol Hematol
. 2024 Aug;
202:104469.
PMID: 39111459
Ovarian carcinoma remains the most lethal gynaecologic malignancy. Half of all high-grade serous ovarian cancers (HGSOCs) have a homologous recombination deficiency (HRD) with regard to the repair of double-strand DNA...
7.
8.
Rabehi T, Quesada S
Bull Cancer
. 2023 Sep;
110(12):1230-1231.
PMID: 37704495
No abstract available.
9.
Quesada S, Thomas Q, Colombo P, Fiteni F
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509219
In spite of tremendous advances in advanced ovarian cancer management through the past decade, notably owing to surgical expertise and novel combination molecules (including bevacizumab and PARP inhibitors), the optimal...
10.
Quesada S, Lebreton C, Caux C, Italiano A, Dubois B
Bull Cancer
. 2023 May;
110(6):657-664.
PMID: 37150731
Tertiary lymphoid structures (TLS) are inducible ectopic lymphoid aggregates, which form in response to various inflammatory situations, including cancer. TLS are notably composed of B lymphocytes, T lymphocytes, mature dendritic...